Dr Doug Gurr
Chairman of The Board of Trustees and Chairman of the Nominations Committee
Dr Doug Gurr became President of Amazon China in 2014 after joining Amazon UK in 2011. He has been a Trustee of the Landmark Trust since 2014. Dr Gurr was a Trustee of the Science Museum from 2004-2014 and was Chairman between 2010 and 2014. From 2006 to 2011 he was Executive Development Director at Asda and a main Board Director of Asda Group Limited. He spent five years as Chief Executive at Blueheath - the internet-enabled stockless wholesaler he founded in 2001. He was a partner at McKinsey and Company from 1995 to 2001, and head of the UK retail practice. He read Mathematics at the University of Cambridge and has a PhD in Theoretical Computer Science from the University of Edinburgh.
Doug joined the Board of Trustees as Chair in October 2015. He is also Chair of the Nominations Committee.
Andrew Balfour LLB
Trustee and Council Member
Andrew Balfour is a retired solicitor who now spends his time working for a number of charities and educational institutions.
He retired from the international law firm Slaughter and May in 2011 after a career of over thirty years working for the firm. During that career he worked on a range of commercial transactions, but was primarily a financing lawyer advising on major borrowing transactions for many leading corporate and bank clients in the UK and elsewhere. Andrew became a partner of Slaughter and May in 1988, worked in the firm’s New York office for a couple of years in the early 1990s and became head of the financing practice and a member of the partnership board in 2004.
In addition to his role for the BHF, Andrew is a trustee of Sustrans (the sustainable transport charity which is developing the National Cycle Network) and of Farleigh Hospice in Essex and is also a school governor.
In his spare time Andrew and his wife, Anne, enjoy being outside in the fresh air in Essex, where they live. They have supported the BHF for many years, following in the footsteps of Anne’s mother who was a leading fundraiser for the BHF in Winchester in the 1970s and 1980s. Andrew also enjoys watching sport, going to the theatre and cinema, gardening and walking and cycling in the countryside.
Andrew joined the BHF Council in 2011 and the Board of Trustees in 2012.
Professor Dame Anna F Dominiczak OBE MD FRCP FRSE FMedSci
Trustee and Council Member
Professor Anna Dominiczak is Regius Professor of Medicine, Vice Principal and Head of College of Medical, Veterinary and Life Sciences, the largest of four Colleges at the University of Glasgow. She is also an honorary consultant physician and non-executive member of the NHS Greater Glasgow and Clyde Health Board.
A graduate of the Medical School in Gdansk, Poland, she is one of the world’s leading cardiovascular scientists and clinical academics. She held a British Heart Foundation Chair of Cardiovascular Medicine at the University of Glasgow between 1997 and 2010, as well as the directorship of the Cardiovascular Research Centre between 2000 and 2010. Her major research interests are in hypertension, cardiovascular genomics and systems medicine and her total research income in the last three years totals more than £30 million.
Prof Dominiczak is a Fellow of the Royal College of Physicians, the Academy of Medical Sciences, the Royal Society of Edinburgh, the American Heart Association and the European Society of Cardiology as well as a member of the Association of Physicians of Great Britain and Ireland, the European Society of Hypertension, the International Society of Hypertension, Society of Endocrinology, British Hypertension Society and British Cardiovascular Society. In 2012 she was invited to join the Council of the Academy of Medical Sciences and elected Vice President, Life Sciences of the Royal Society of Edinburgh.
She is currently President of the European Society of Hypertension, and a member of the Leadership Committee of the Council for High Blood Pressure Research of the American Heart Association. In addition to membership of several editorial boards, Professor Dominiczak has held several senior editorial positions and is currently Editor-in-Chief of Hypertension.
With more than 250 publications in peer-reviewed journals, and numerous scientific awards, her services to medicine were recognised by the Queen who awarded her with an OBE in 2005 and a DBE in 2016.
Professor Dominiczak joined the board of Trustees in 2014.
Dr. Robert Easton BSc ARCS DPhil
Trustee and Chair of the Fundraising Board
Dr Robert Easton is a Partner and Managing Director of The Carlyle Group, the major global alternative asset manager, and currently heads the firm’s private equity fund in Ireland.
Previously, he was co-head of Carlyle Europe Technology Partners, a fund targeting Europe-wide growth capital and buyout transactions in the media, software, telecom and healthcare sectors, and prior to that he ran the firm’s UK buyout activities. He is based in London and has been with Carlyle for 13 years.
Prior to joining Carlyle, Dr Easton was Vice President of Corporate Development at Invensys plc. He was a key figure in the mid-nineties transformation of BTR from a diversified conglomerate to a focused engineering group and, following the merger of BTR and Siebe to form Invensys in 1999, in the further focusing of Invensys to become a leading Automation and Controls group.
Dr Easton joined BTR in 1996 from Trafalgar House, another major UK engineering group where he was Director of Corporate Finance and Planning. Prior to this he spent eight years in the investment banking business working initially for CSFB and then for Wasserstein Perella.
Dr Easton has a first class honours degree in chemistry from Imperial College in London and a Doctorate in organic synthesis from Oxford University.
In addition to his Directorships of Carlyle portfolio companies, Dr Easton is a past Chairman of the British Venture Capital Association, the trade association for private equity in the UK, and he currently sits on two boards at Imperial College, the Advisory Board of the Business School and the private sector Syndicate over-seeing the development if a new University campus at Imperial West.
He became a Trustee in August 2013 and is also Chair of the BHF Fundraising Board.
Rt Hon Lord Feldman of Elstree
Andrew Feldman served as Chairman of the Conservative Party from 2010 to 2016. Andrew attended Political Cabinet, ran the professional operation at Conservative Campaign Headquarters (CCHQ) and had overall responsibility for the Party’s strategy, finances, and professional operation leading up to the 2015 General Election.
Before being appointed Party Chairman, Andrew was Chief Executive of the Conservative Party and part of the senior team running the 2010 General Election campaign. Prior to that Andrew was Chief Executive of his family textile business, in practice as a commercial Barrister at 1 Essex Court and an associate consultant at Bain & Co.
Andrew graduated with a first in jurisprudence from Brasenose College Oxford and attended the Inns of Court School of Law. Andrew was elevated to the House of Lords in 2010 and appointed to the Privy Council in 2015.
Andrew is currently chairman of his family textile business and a Senior Adviser to Macro Advisory Partners, Tetragon Asset Management, TowerBrook Capital Partners and the Noé Group. Andrew is also a Trustee of Policy Exchange, a Board Member of the UK Holocaust Memorial Foundation and a Member of the Advisory Board of the Community Security Trust.
Daryl Fielding BSc
Daryl is a portfolio director with roles including CEO of The Marketing Academy Foundation, NED at Isobel Advertising, Trustee of Pelican Cancer Foundation and is a consultant in brand strategy and marketing. She is a Fellow of the Marketing Society, on the Executive Committee of Women in Advertising and Communications, London and a tutor for The Incorporated Society of British Advertisers.
She was a Director at Vodafone UK, Mondelez Europe and Independent Newspapers. As Director of Brand at Vodafone, she was responsible for brand strategy and all on and off-line marketing materials. As VP Marketing for Mondelez, she led the marketing policy for the region and marketing for their top ten brands. Prior to that she was Commercial Director of Independent Newspapers. Her advertising agency career spans 20 years at Ogilvy, Lowe Lintas and DDB where highlights were leading Dove’s Campaign for Real Beauty and New Labour’s advertising in the 1997 Election.
Her first degree was in Physiology, she studied and taught in the medical school at Kings College, London and even now retains an interest in all things bodily. She splits her time between London and Dorset, enjoys scuba diving, travel, opera and the arts.
Professor John P Iredale
John Iredale is Pro Vice Chancellor Health at the University of Bristol. He holds the chair of Experimental Medicine, and his areas of leadership and responsibility are for the research, teaching and management strategy for the Schools of Medicine, Veterinary Medicine, Dentistry and Biomedical Sciences across the relevant Faculties at the University of Bristol.
He also holds Honorary Consultant contracts with the North Bristol NHS Trust and the University Hospitals Bristol Foundation Trust. Previously Professor Iredale was the Regius Chair of Medical Science, Dean of Clinical Medicine and Vice Principal Health Services at the University of Edinburgh where he led the Medical School. He has previously held the Chair of Medicine in Edinburgh (2006-2013), the chair of Medicine at the University of Southampton (2004-2006) and a Personal Chair in Hepatology (2000-2004). From 2010 to 2016, Prof Iredale was a Non-Executive Director of NHS Lothian.
Professor Iredale graduated from the University of Southampton with honours in Clinical Distinction in 1985 and was awarded a DM in 1995. He was made a Fellow of the Royal College of Physicians of London in 1999 and The Royal College of Physicians of Edinburgh in 2007. He was made a Fellow of the Academy of Medical Sciences in 2003 and Fellow of the Royal Society of Edinburgh in 2011.
Professor Iredale joined the Board of Trustees in November 2016.
Professor David Lomas
Professor David Lomas PhD, ScD, FHEA, FRCP, FMedSci is Vice Provost (Health), Head of UCL School of Life and Medical Sciences and Head of UCL Medical School. He is the Academic Director of the UCL Partners Academic Health Sciences Centre.
David is an NIHR Senior Investigator and works as a respiratory physician at UCLH and the Royal Free Hospital. He was Chair of the Population and Systems Medicines Board at the Medical Research Council and previously chaired the Respiratory Therapy Area Unit Board at GlaxoSmithKline.
David chaired the Scientific Priorities Committee for the 100,000 genomes project and serves as Deputy Chair of the Scientific Advisory Committee for Genomics England. He was a member of the Expert Advisory Group for the UK Minister of Life Sciences Innovative Medicines and MedTech Review.
Professor Lomas joined the Board of Trustees in November 2016.
Chair of the Audit & Risk Committee
Iain Mackay is Group Finance Director of HSBC Holdings Plc, a role he has held since December 2010. Iain joined HSBC in 2007 as CFO of HSBC North America Holdings Inc where he was instrumental in the restructuring of HSBC's consumer finance business. From 2009-2010 he was CFO Asia Pacific of HSBC Holdings Plc. Before joining HSBC, Iain was at General Electrics - initially as Controller of the Global Consumer Finance unit, then CFO of GE Healthcare - Global Diagnostic Imaging. From 1990-1996, Iain was a regional finance director with Schlumberger Dowell. Early in his career, Iain was with PriceWaterhouse in New York and Paris and Thomson McLintock, KMG in the UK.
Iain joined the Board of Trustees in October 2015, and is Chair of the BHF Audit & Risk Committee.
Professor Sussan Nourshargh PhD FBPhS FSB FMedSci
Sussan Nourshargh is a pharmacologist who studied at University College London and King’s College London and became Professor of Immunopharmacology at Imperial College London in 2006. In 2007 she joined Barts and The London Medical School, Queen Mary, University of London, to establish and head a new Centre focusing on Microvascular Research. Her research focuses on unravelling the molecular and cellular events involved in leukocyte trafficking and through the application of advanced in vivo imaging modalities she has made seminal contributions to the fields of inflammation and vascular biology.
Professor Nourshargh is a Wellcome Trust Senior Investigator and Fellow of the Academy of Medical Sciences, British Pharmacological Society and Royal Society of Biology. She has acted on numerous funding Boards including BHF Project Grant and Fellowship Committees and is currently on the Board of the Wellcome Trust’s Biomedical Resources & Multi-User Equipment Committee, Royal Society’s Newton Advanced Fellowship Panel and she chairs the Academy of Medical Sciences Committee for selection of new Fellows in the fields of pharmacology, physiology and neurosciences. Sussan has also been on the panel of numerous national and international scientific advisory boards, has been recipient of several prestigious scientific awards, has held a number of editorial positions and is currently on the Editorial Board of the European Journal of Immunology.
Professor Nourshargh joined the Board of Trustees in October 2015.
Peter received his MA from Cambridge in Philosophy and, recently, an Advanced Diploma in History from Oxford.
Peter has spent 30 years in the media industry, holding board positions in the UK, USA, India and Australia. For many years he was a Board Director of BBC Worldwide Ltd, for whom he developed and ran BBC Magazines; he was also President and CEO of BBC Worldwide Americas Inc, launching some TV channels and chairing a joint venture with Discovery Inc.
Peter was recently Deputy Chairman of Immediate Media Co, a large PE-backed magazine and digital company and is currently Chairman of Texere Publishing, a VC-backed cross-media publisher for the science and medical markets, Chairman of Bell, an education business and he sits on the Board of The National Archives. Peter also Chairs Wildscreen, a media-related conservation charity and has founded East West Relations Ltd. to help western media companies identify and secure opportunities in India, where he was born.
Peter has competed in many triathlons and is these days more of a cyclist, cycling the length of Britain and in sportives.
Peter has had his own heart issues in the past, undergoing a heart bypass in 2011 following a heart attack.
Professor Liam Smeeth
Trustee and Council Member
Liam Smeeth is professor of clinical epidemiology and Head of the Department of Non-communicable Disease Epidemiology at the London School of Hygiene and Tropical Medicine. He also undertakes clinical work as a general practitioner in north London. Much of his research is based on making better use of computerised clinical data both to investigate drug effects and disease aetiology. He holds a Wellcome Trust Senior Fellowship in Clinical Science and is Deputy Director of the Farr Institute London, one of the four UK Health Informatics Research Centres. His work is largely in cardiovascular disease, with one area of particular interest being the causal role of infections and inflammation. Other areas of interest are genetic epidemiology and non-communicable diseases in low income settings. He is involved in a range of activities for NICE and the NHS more widely.
Professor Sir Kent Woods
Vice Chair and Chair of the Advisory Council
Sir Kent Woods was the Chief Executive of the Medicines and Healthcare Products Regulatory Agency (MHRA) 2004-2013 and Chairman of the Management Board of the European Medicines Agency 2011-2015. He was previously Director of the NHS Health Technology Assessment Programme (1999-2003), commissioning research in and for the NHS.
A graduate of Cambridge and of Harvard School of Public Health, he was a consultant physician in cardiovascular medicine at Leicester Royal Infirmary from 1984-2003 and is Emeritus Professor of Therapeutics at Leicester University. He is a Fellow of the Academy of Medical Sciences and was knighted for services to healthcare in 2011.
Sir Kent joined the Board as Vice Chair, and Chair of the Advisory Council and in October 2015.